198 related articles for article (PubMed ID: 33046806)
1. Effects of olanzapine treatment on lipid profiles in patients with schizophrenia: a systematic review and meta-analysis.
Li R; Zhang Y; Zhu W; Ding C; Dai W; Su X; Dai W; Xiao J; Xing Z; Huang X
Sci Rep; 2020 Oct; 10(1):17028. PubMed ID: 33046806
[TBL] [Abstract][Full Text] [Related]
2. Lipid profile in schizophrenia: case control study.
Mhalla A; Bel Hadj Salah W; Mensi R; Amamou B; Messaoud A; Gassab L; Douki W; Najjar MF; Gaha L
Tunis Med; 2018 Jan; 96(1):22-29. PubMed ID: 30324988
[TBL] [Abstract][Full Text] [Related]
3. Effect on lipid profiles of switching from olanzapine to another second-generation antipsychotic agent in veterans with schizophrenia.
Garman PM; Ried LD; Bengtson MA; Hsu C; McConkey JR
J Am Pharm Assoc (2003); 2007; 47(3):373-8. PubMed ID: 17510032
[TBL] [Abstract][Full Text] [Related]
4. Association of blood cell counts with the risk of olanzapine- or clozapine-induced dyslipidemia in Chinese schizophrenia patients.
Xiong Z; Cheng M; Zhu P; Huang S; Guo J; Zhang W; Zhou H; Shu Y; Li Q
Hum Psychopharmacol; 2019 Jul; 34(4):e2699. PubMed ID: 31273857
[TBL] [Abstract][Full Text] [Related]
5. Comparison of fasting blood sugar and serum lipid profile changes after treatment with atypical antipsychotics olanzapine and risperidone.
Kaushal J; Bhutani G; Gupta R
Singapore Med J; 2012 Jul; 53(7):488-92. PubMed ID: 22815019
[TBL] [Abstract][Full Text] [Related]
6. Serum lipid profiles and schizophrenia: effects of conventional or atypical antipsychotic drugs in Taiwan.
Huang TL; Chen JF
Schizophr Res; 2005 Dec; 80(1):55-9. PubMed ID: 15964176
[TBL] [Abstract][Full Text] [Related]
7. [Effects of ziprasidone and olanzapine on glucose and lipid metabolism in first-episode schizophrenia].
Shao P; Ou J; Wu R; Fang M; Chen H; Xu Y; Zhao J
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2013 Apr; 38(4):365-9. PubMed ID: 23645236
[TBL] [Abstract][Full Text] [Related]
8. Serum IL-1ra, a novel biomarker predicting olanzapine-induced hypercholesterolemia and hyperleptinemia in schizophrenia.
Lin Y; Peng Y; He S; Xu J; Shi Y; Su Y; Zhu C; Zhang X; Zhou R; Cui D
Prog Neuropsychopharmacol Biol Psychiatry; 2018 Jun; 84(Pt A):71-78. PubMed ID: 29410009
[TBL] [Abstract][Full Text] [Related]
9. Effect of lurasidone versus olanzapine on cardiometabolic parameters in unmedicated patients with schizophrenia: a randomized controlled trial.
Jena M; Mishra A; Mishra BR; Nath S; Maiti R
Psychopharmacology (Berl); 2020 Nov; 237(11):3471-3480. PubMed ID: 32740676
[TBL] [Abstract][Full Text] [Related]
10. Effects of olanzapine and risperidone on lipid metabolism in chronic schizophrenic patients with long-term antipsychotic treatment: a randomized five month study.
Smith RC; Lindenmayer JP; Hu Q; Kelly E; Viviano TF; Cornwell J; Vaidhyanathaswamy S; Marcovina S; Davis JM
Schizophr Res; 2010 Jul; 120(1-3):204-9. PubMed ID: 20457512
[TBL] [Abstract][Full Text] [Related]
11. Allelic variation in ApoC3, ApoA5 and LPL genes and first and second generation antipsychotic effects on serum lipids in patients with schizophrenia.
Smith RC; Segman RH; Golcer-Dubner T; Pavlov V; Lerer B
Pharmacogenomics J; 2008 Jun; 8(3):228-36. PubMed ID: 17726453
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness of long-term aripiprazole therapy in patients with acutely relapsing or chronic, stable schizophrenia: a 52-week, open-label comparison with olanzapine.
Chrzanowski WK; Marcus RN; Torbeyns A; Nyilas M; McQuade RD
Psychopharmacology (Berl); 2006 Dec; 189(2):259-66. PubMed ID: 17058105
[TBL] [Abstract][Full Text] [Related]
13. A retrospective comparison of weight, lipid, and glucose changes between risperidone- and olanzapine-treated inpatients: metabolic outcomes after 1 year.
Meyer JM
J Clin Psychiatry; 2002 May; 63(5):425-33. PubMed ID: 12019668
[TBL] [Abstract][Full Text] [Related]
14. Metabolomic mapping of atypical antipsychotic effects in schizophrenia.
Kaddurah-Daouk R; McEvoy J; Baillie RA; Lee D; Yao JK; Doraiswamy PM; Krishnan KR
Mol Psychiatry; 2007 Oct; 12(10):934-45. PubMed ID: 17440431
[TBL] [Abstract][Full Text] [Related]
15. Cross-sectional comparison of fasting lipids in normoglycemic patients with schizophrenia during chronic treatment with olanzapine, risperidone, or typical antipsychotics.
Hardy TA; Marquez E; Kryzhanovskaya L; Taylor CC; Cavazzoni P
J Clin Psychopharmacol; 2006 Aug; 26(4):405-8. PubMed ID: 16855460
[TBL] [Abstract][Full Text] [Related]
16. Latent Toxoplasma gondii infection is associated with decreased serum triglyceride to high-density lipoprotein cholesterol ratio in male patients with schizophrenia.
Sagud M; Vlatkovic S; Svob Strac D; Sviben M; Zivkovic M; Vilibic M; Vuksan-Cusa B; Mihaljevic-Peles A; Pivac N
Compr Psychiatry; 2018 Apr; 82():115-120. PubMed ID: 29477703
[TBL] [Abstract][Full Text] [Related]
17. High-density lipoprotein-cholesterol and antipsychotic medication in overweight inpatients with schizophrenia: post-hoc analysis of a Japanese nationwide survey.
Ono S; Sugai T; Suzuki Y; Yamazaki M; Shimoda K; Mori T; Ozeki Y; Matsuda H; Sugawara N; Yasui-Furukori N; Okamoto K; Sagae T; Someya T
BMC Psychiatry; 2018 Jun; 18(1):180. PubMed ID: 29879941
[TBL] [Abstract][Full Text] [Related]
18. A crossover study on lipid and weight changes associated with olanzapine and risperidone.
Su KP; Wu PL; Pariante CM
Psychopharmacology (Berl); 2005 Dec; 183(3):383-6. PubMed ID: 16240162
[TBL] [Abstract][Full Text] [Related]
19. Comparison of metabolic changes in patients with schizophrenia during randomized treatment with intramuscular olanzapine long-acting injection versus oral olanzapine.
McDonnell DP; Kryzhanovskaya LA; Zhao F; Detke HC; Feldman PD
Hum Psychopharmacol; 2011 Aug; 26(6):422-33. PubMed ID: 21823172
[TBL] [Abstract][Full Text] [Related]
20. Meta-analysis of ghrelin alterations in schizophrenia: Effects of olanzapine.
Goetz RL; Miller BJ
Schizophr Res; 2019 Apr; 206():21-26. PubMed ID: 30528312
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
